Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (GERN) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class therapies for cancer. The company's cornerstone product candidate is Imetelstat, a novel telomerase inhibitor currently in clinical development. Telomerase is an enzyme that allows cancer cells to maintain telomere length, essential for limitless cellular replication.
Imetelstat is a potent, specific inhibitor of telomerase and holds promise for treating various hematologic myeloid malignancies. Based on clinical data obtained in late 2012, Geron is exploring the potential of Imetelstat to treat conditions such as myelofibrosis (MF), myelodysplastic syndromes (MDS), and acute myelogenous leukemia (AML).
Geron earns revenue through a mix of collaboration agreements, milestones, royalties, and licensing arrangements. The company is the exclusive developer of Imetelstat and possesses various rights to the drug. Operating as a single segment focused on oncology, Geron is committed to advancing its research to bring effective cancer treatments to market.
Stay updated with the latest news and developments from Geron Corporation to learn more about their groundbreaking research and progress in cancer treatment.
Geron Corporation (NASDAQ: GERN) announced that data from the pivotal IMerge Phase 3 clinical trial of its telomerase inhibitor, imetelstat, in lower-risk myelodysplastic syndromes (MDS) is scheduled for oral presentation at the 2023 ASCO Annual Meeting in Chicago. The study evaluates imetelstat in patients who are transfusion dependent and have relapsed or are refractory to erythropoiesis-stimulating agents. The primary efficacy endpoint is the rate of red blood cell transfusion independence lasting at least eight weeks, with secondary endpoints focusing on longer durations and hematologic improvement. The trial enrolled 178 patients across multiple regions. Geron plans to submit a New Drug Application in mid-2023 and a Marketing Authorization Application in the EU later this year.
Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options to acquire 1,684,220 shares of common stock as an employment inducement for newly hired employees. The options were issued on April 19, 2023, at an exercise price of $2.49 per share, equal to the stock's closing price that day. Of the total, 1,586,000 options have a 10-year term and vest over four years, with an initial 12.5% vesting after six months. The remaining shares will vest monthly over the following 42 months. The remaining 98,220 options will vest upon achieving specific regulatory milestones. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and follows Geron’s 2018 Inducement Award Plan.
Geron focuses on therapies for hematologic malignancies, particularly its investigational telomerase inhibitor, imetelstat.
FAQ
What is the current stock price of Geron (GERN)?
What is the market cap of Geron (GERN)?
What is the primary focus of Geron Corporation?
What is Imetelstat?
Which conditions is Imetelstat being developed to treat?
How does Imetelstat work?
What revenue streams does Geron Corporation rely on?
Is Geron Corporation a diversified company?
What is the significance of telomerase in cancer treatment?
Has Geron Corporation achieved any significant milestones?
Where can I find the latest news about Geron Corporation?
What makes Imetelstat unique among cancer therapies?
